EMEIS : Is the distribution phase coming to an end ?
| Entry price | Target | Stop-loss | Potential |
|---|
|
€87.92 |
€96.5 |
€83.9 |
+9.76% |
|---|
Orpéa shares are locked into a trading range. This phase will eventually have to end with a return of a clear trend.
Strengths● The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at EUR 84.44 EUR in weekly data.
● Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 84.44 support.
● There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
● One of the major weak points of the company is its financial situation.
● The firm trades with high earnings multiples: 24.51 times its 2018 earnings per share.
● The underlying tendency is negative on the weekly chart below the resistance at 101.25 EUR
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
EMEIS 
